Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2-metastatic breast cancer: Results of the phase III STIC CTC trial - Bidard, F C; Jacot, W; Dureau, S (Cancer Res, 2019)
et al.